Myonectin Predicts the Development of Type 2 Diabetes

Area of Science:

• Endocrinology
• Metabolic Disease Research
• Biomarker Discovery

Background:

• Myonectin is a myokine primarily expressed in skeletal muscle.
• The clinical significance of myonectin, particularly in relation to metabolic disorders, remains largely unexplored.

Purpose of the Study:

• To investigate the association between myonectin levels and type 2 diabetes mellitus (T2DM).
• To explore the relationship between myonectin and insulin resistance markers in cross-sectional and interventional settings.

Main Methods:

• Cross-sectional study involving individuals with newly diagnosed T2DM, impaired glucose tolerance (IGT), and healthy controls.
• Interventional studies included oral glucose tolerance tests, exercise, lipid infusions, and euglycemic-hyperinsulinemic clamps (EHCs).
• Circulating myonectin was quantified using enzyme-linked immunosorbent assay (ELISA).

Main Results:

• Individuals with T2DM and IGT exhibited significantly higher circulating myonectin concentrations compared to healthy controls.
• Plasma myonectin positively correlated with various metabolic risk factors, including waist/hip ratio, body fat percentage, triglycerides, fasting glucose, HbA1c, and HOMA-IR.
• Multivariate analysis confirmed a significant correlation between myonectin levels and the presence of IGT and T2DM.
• Short-term interventions like exercise, glucose challenge, lipid infusion, or EHC did not significantly alter myonectin levels.

Conclusions:

• Elevated circulating myonectin levels are associated with impaired glucose tolerance and type 2 diabetes.
• Myonectin may serve as a valuable predictive biomarker for the development of prediabetes and diabetes.
• Further research is warranted to elucidate the precise role of myonectin in glucose metabolism and diabetes pathogenesis.